Siegfried AG Exhibits Strong Financial Growth Amid Challenges

In 2025, Siegfried AG achieved notable financial success, driven by disciplined execution and operational efficiency. The company reported net sales of CHF 1,327.8 million, experiencing a growth of 4.3% in local currencies. Net sales from the Drug Substances and Drug Products clusters grew by 4.3% and 4.3% in local currencies, respectively.

Core EBITDA rose to CHF 312.3 million, reflecting a margin boost to 23.5%. This performance underscores Siegfried's robust earnings quality. Despite macroeconomic volatility, Siegfried maintained a solid balance sheet with a net debt-to-core EBITDA ratio of 1.5.

Siegfried pursued strategic investments, notably acquiring US small molecule drug substance capacity. The company continues to enhance its capabilities with technology upgrades, aligning with its EVOLVE+ strategy. The outlook for 2026 suggests low-single-digit growth, with profitability expected to remain strong.